PharmEasy parent slashes FY26 loss by 67% to ₹520 Cr

API Holdings, the parent company of online pharmacy PharmEasy, cut its consolidated net loss by 67% to ₹520 crore in the fiscal year ended March 2026, Inc42 reported. The improvement follows cost-control measures implemented in recent years, including operational adjustments that began after its earlier struggles.

While the loss reduction is steep, the company continues to burn cash, raising questions about its runway without additional funding. PharmEasy’s growth has moderated, with its gross merchandise value expanding at a slower pace compared to some peers in the sector.

The timing is notable. Twenty-two Indian startups went public in FY26, reopening the IPO window after a period of limited activity, but PharmEasy was not among them. Investors who backed the company at high valuations in past funding rounds may now face challenges if the trend doesn’t accelerate.

For now, the focus appears to be on sustainability. PharmEasy’s path mirrors that of other late-stage startups—where revenue growth has not always translated into profitability—highlighting the difficulty of achieving sustainable margins in competitive markets.

Sources: inc42.com